By Donna Loyle, communications specialist, LIMR
Researchers seek patients diagnosed with node-positive or high-risk node negative triple negative invasive breast cancer for a randomized phase III treatment trial. There are two treatment arms. All study participants receive the medications doxorubicin hydrochloride, cyclophosphamide and paclitaxel. Those in Arm 2 also receive carboplatin.
Study #BR003 is available at all Main Line Health acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. More information is available at: https://www.mainlinehealth.org/research/clinical-trials/nrg-br003